Wheeler Bio Secures $35M in Oversubscribed Series A-1 Financing

• Wheeler Bio has closed a $35 million oversubscribed Series A-1 financing round, led by Alloy Therapeutics and Echo Investment Capital, with participation from Mitsubishi Corporation (Americas), Germin8 Ventures, and Russell Westbrook Enterprises.

• The funding will support the expansion of Wheeler’s CDMO capabilities, including plans for a new 52,000-square-foot large-scale biologics manufacturing facility in Oklahoma City.

Wheeler Bio, a contract development and manufacturing organization (CDMO) specializing in antibody-based therapies, has secured $35 million in an oversubscribed Series A-1 financing round. The investment was led by Alloy Therapeutics and Echo Investment Capital, with additional support from Mitsubishi Corporation (Americas), Germin8 Ventures, and Russell Westbrook Enterprises.

The financing will enable Wheeler Bio to expand its process development and cGMP manufacturing capabilities. A key focus of this expansion includes planning the construction of a 52,000-square-foot large-scale biologics manufacturing facility adjacent to a biomanufacturing workforce training center at Convergence in the Oklahoma City Innovation District.

“This investment will fuel Wheeler’s ongoing efforts to expand its partner base, team, and capabilities in order to accelerate the advancement of our partners’ therapies,” said Patrick Lucy, President and Chief Executive Officer of Wheeler Bio.

The company’s Modular CMC platform underpins its high-science approach, supporting clients from early development to clinical and commercial manufacturing. The new funding will help scale Wheeler Bio’s footprint in Oklahoma City and beyond, as well as strengthen collaborations with key investors.